Purchase this article with an account.
M. M. Hom; Use of 0.5% Loteprednol for Contact Lens Intolerance and Dryness. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1530.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
CL related dryness is the primary cause for CL dropouts. The use of loteprednol for previous CL failures was studied.
23 patients refitted into daily wear PureVision lenses and ReNu MultiPlus care systems were seen in crossover, randomized, investigator-masked study comparing loteprednol and rewetter drops. There were two four week phases: Loteprednol phase (LOT): loteprednol BID without lenses and Renu Rewetting drops up to QID with lenses on and rewetter phase (REW): Renu Rewetting drops BID without lenses and Renu Rewetting drops up to QID with lenses on.
For "Ocular Surface Disease Index" (OSDI), no significant differences were seen between visits for REW phase. Statistically significant improvement in OSDI scores was seen for LOT from baseline to 4 weeks (baseline mean 35.47 SD 31.51, 4 weeks mean 23.67 SD 21.55; p= .049) For "Subjective Evaluation of Symptoms of Dryness" (SESoD) (scores 0 to 4), no significant difference seen between visits for REW phase. For LOT, significant improvement in SESoD scores occurred from baseline to 4 weeks (baseline mean 2.61 SD 0.86, 4 weeks mean 2.0 SD 1.18; p= .019) For fluorescein conjunctival staining (scores 0 to 4 over 6 zones), LOT showed significant decrease in staining in superior nasal (superior nasal baseline mean 1.80 SD 0.83, at 4 weeks mean 1.38 SD .79; p= .01) and inferior nasal zones (inferior nasal baseline mean 1.76 SD .95, at 4 weeks mean 1.26 SD .98; p= .01). REW showed significant increase in staining for inferior nasal zones. (inferior nasal baseline mean 1.42 SD .85, at 4 weeks mean 1.97 SD .92; p= .01). REW showed directional trend towards an increase in staining for superior nasal zone. (superior nasal baseline mean 1.73 SD 0.83, at 4 weeks mean 1.97 SD .92; p= .07) There were no significant differences for the other zones. For corneal staining (scores 0 to 4 over 5 zones), LOT showed a significant reduction of staining in superior cornea (baseline mean 0.14 SD 0.35, at 4 weeks mean 0.11 SD 0.32;p= .02). REW showed no significant reduction in superior zone. There was a significant increase for LOT in temporal zone (baseline mean .04 SD .21, at 4 weeks mean .26 SD 0.7; p= .04). There was no significant reduction in the other zones for LOT or REW.
0.5% loteprednol improved both signs and symptoms of CL dryness for previous failures.
Clinical Trial: :
This PDF is available to Subscribers Only